Understand the source comparison
Peptides for Tennis Elbow: Method Comparison
BPC-157 (local injection) VEGF upregulation, angiogenesis promotion 4–8 weeks for pain reduction, 12+ weeks for structural improvement Case series, animal models. No Phase 3 RCTs Most direct mechanism for hypoxic tendon tissue; requires precise injection techn
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157 (local injection)
- VEGF upregulation, angiogenesis promotion
- 4–8 weeks for pain reduction, 12+ weeks for structural improvement
- Case series, animal models. No Phase 3 RCTs
- Most direct mechanism for hypoxic tendon tissue; requires precise injection technique
- TB-500 (subcutaneous administration)
- Actin polymerization, cell migration, cytokine modulation
- 6–10 weeks for collagen remodeling
- Preclinical models, limited human data
- Strong anti-inflammatory profile; systemic rather than localized effect
- CJC-1295 + Ipamorelin
- IGF-1 elevation, satellite cell activation
- 8–12 weeks for measurable tendon quality improvement
- Indirect evidence from GH therapy studies
- Supports overall tissue repair but lacks injury-specific targeting
- Corticosteroid injection (standard care)
- Inflammatory suppression
- 2–4 weeks for symptom relief, no structural benefit
- Multiple RCTs. Established but limited long-term efficacy
- Fast symptom control but does not address collagen degradation; reinjury rates high
- Eccentric loading alone
- Mechanical stimulus for collagen remodeling
- 12–16 weeks for sustained improvement
- Cochrane review. Level 1 evidence
- Gold standard conservative treatment; peptides enhance this mechanism